BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Monday, March 16, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
May 21, 2009
View Archived Issues
TLK-58747, a DNA alkylator, shows broad antitumor activity and less toxicity in preclinical studies
Read More
CpG-28 appears to benefit some recurrent glioblastoma patients in phase II study
Read More
Small-molecule mTOR inhibitor AZD-8055 shows potent antitumor activity in preclinical studies
Read More
Sanofi-aventis and DNDi sign collaboration agreement for fexinidazole for sleeping sickness
Read More
GSK presents update on development of A (H1N1) adjuvanted influenza vaccine
Read More
Merck Serono withdraws offer for reproductive technology company MediCult
Read More
PF-3084014 displays preclinical antitumor activity in several models
Read More
GlaxoSmithKline targets AKT1 with GSK-1720070
Read More
Second generation proteasome inhibitor developed at Millennium Pharmaceuticals
Read More
Novel polyene compound, corifungin, displays potent antifungal activity in vitro
Read More
Biovail acquires worldwide rights to tetrabenazine from Cambridge Laboratories
Read More
Biopure presents an update on the NMRC's clinical development of Hemopure
Read More
Genentech and Biogen Idec submit two sBLAs to FDA for Rituxan in CLL
Read More
GW Pharmaceuticals files regulatory submission in the U.K. and Spain for Sativex in MS
Read More
IDMB recommends continuation of phase III AGENDA trial of Genta's Genasense
Read More
Endotis Pharma reports successful completion of phase I EP-42675 program
Read More
Janssen claims novel adenosine A2A receptor antagonists for neurodegenerative conditions
Read More
Merck KGaA discovers SGLT inhibitors for the treatment of diabetes
Read More
Preclinical studies point to potential of GS-9411 for cystic fibrosis
Read More
Eisai claims novel cytidine deaminase inhibitors for the treatment of cancer
Read More
Active first quarter at Bristol-Myers Squibb
Read More
Younger macular degeneration patients more likely to benefit from VEGF Trap-Eye
Read More
Potassium channel blocker WYE-160020 reduces atrial fibrillation inducibility in canine models
Read More
Pharmacologic chaperone of mutant opsin, BIK-381, for the treatment of retinal degeneration
Read More
Mipomersen study meets endpoints in homozygous familial hypercholesterolemia
Read More
First two stages of Verona's phase I/IIa RPL-554 trial yields positive results
Read More
FDA grants orphan drug designation for MediGene's EndoTAG-1
Read More
